Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × NIH × Proteus Syndrome × Clear all

Phase

Phase 2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 136 Melanoma 123 Lymphoma 110 Prostatic Neoplasms 108 Carcinoma, Non-Small-Cell Lung 98 Multiple Myeloma 86 Carcinoma, Renal Cell 85 Sarcoma 78 Ovarian Neoplasms 77 Leukemia, Myeloid, Acute 72 Leukemia 72 Colorectal Neoplasms 72 Leukemia, Lymphocytic, Chronic, B-Cell 70 Lung Neoplasms 69 Colonic Neoplasms 68 Lymphoma, Non-Hodgkin 67 Rectal Neoplasms 66 Pancreatic Neoplasms 61 Lymphoma, Large B-Cell, Diffuse 61 Carcinoma, Ovarian Epithelial 61 Neoplasms 59 Precursor Cell Lymphoblastic Leukemia-Lymphoma 57 Brain Neoplasms 57 Lymphoma, Follicular 55 Kidney Neoplasms 52 Lymphoma, Mantle-Cell 47 Glioblastoma 47 Fallopian Tube Neoplasms 47 Neoplasm Metastasis 46 Burkitt Lymphoma 46

Interventions

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04316546 2026-03-11

MK-7075 (Miransertib) in Proteus Syndrome

National Institutes of Health Clinical Center (CC)

Phase 2 Recruiting

Proteus Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon ⚡